Nearly Half of Adolescents Using Semaglutide in Trial Dropped Below the Clinical Cut-Off for Obesity A secondary analysis of the STEP TEENS trial, published in the Obesity journal and presented at the European Congress on Obesity 2023, has found that semaglutide is effective in treating obesity i
In a secondary analysis of the STEP TEENS trial, semaglutide proved to be a significant treatment for adolescent obesity, with 45% of the semaglutide-treated participants losing enough weight to drop below the obesity cutoff, and 74% moved down at least one BMI category after 68 weeks.A secondary analysis of the STEP TEENS trial, published in the Obesity journal and presented at the European Congress on Obesity 2023, has found that semaglutide is effective in treating obesity in adolescents.
The study, led by Aaron S. Kelly, PhD, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, Minneapolis, and colleagues, also showed almost three quarters moved down by at least one weight category., showed the efficacy of semaglutide in helping adolescents lose weight. In this secondary analysis of the STEP TEENS trial, the authors examined the effect of semaglutide treatment on improvement in body mass index categories.
Adolescents aged 12 to under 18 years with BMI in the highest 5% were included in this analysis. Participants were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks; both groups received matching lifestyle counseling. The proportion of participants who achieved an improvement in BMI category from baseline to week 68 was assessed using on-treatment data.
Of 201 adolescents randomized, 62 , 69 and 69 were in OCIII, OCII and OCI, respectively; only one participant had overweight and was excluded from this secondary analysis. At randomization, mean body weight was 107.5 kg and mean BMI was 37.0 kg/mAt week 68, 74% of participants on semaglutide had an improvement of one or more BMI categories versus 19% on placebo. An improvement of ≥2 BMI categories occurred in 45% of participants treated with semaglutide versus 3% with placebo.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Weight-Loss Drugs Might Help People with Obesity Fight CancerAn ingredient in popular drugs used for weight loss, like Ozempic and Wegovy, could help people with obesity fight cancer, according to a new, small study published in the journal Obesity.
Baca lebih lajut »
Weight loss drug reverses obesity for nearly half of teens in studySemaglutide was recently approved by the FDA to help obese adolescents lose weight. When used to treat diabetes, the drug is sold under the brand name Ozempic.
Baca lebih lajut »
Obesity Drug With Swallowable Balloon Boosts Weight LossA combination of a swallowable Allurion gastric balloon and liraglutide delivers higher weight loss (around 19% after mean 4 months) than use of separate treatments.
Baca lebih lajut »
Half of Teens Drop Below Obesity Cutoff With SemaglutideSemaglutide represents an efficacious treatment option for adolescents with obesity, with the potential to reduce BMI below the obesity threshold.
Baca lebih lajut »
Opinion: Ozempic for weight loss is all the rage, but so is fighting fatphobiaYou've read the stories about miracle weight loss drugs? The real miracle would be to stop blaming fat people for being fat.
Baca lebih lajut »
The secret to weight loss could be in your ears: new researchA simple acupuncture technique could reduce food cravings and lower body-mass index, according to Japanese researchers.
Baca lebih lajut »